IP Library › Granted Patent US 11,015,189
Granted Patent B2
US 11,015,189 · App. 15/829,639 · Granted May 25, 2021

AAV capsid proteins for nucleic acid transfer

Inventors: Leszek Lisowski (San Mateo, CA); Mark A. Kay (Los Altos, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University
C12N15/1058C07K14/005C12N7/00C12N2750/14121C12N2750/14122C12N2750/14141C12N2750/14143C12N2750/14151C12N2750/14152
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,015,189
App. No.
15/829,639
Granted
May 25, 2021
Kind
B2
Abstract

Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided.

Claims (15)

1. A method of transfer of a nucleic acid of interest into a mammal, comprising: introducing a recombinant adeno-associated virus (AAV vector into a mammal, the recombinant AAV vector encoding a nucleic acid of interest encapsidated in a capsid protein that has at least 99% sequence identity to SEQ ID NO: 31 or at least 97% sequence identity to SEQ ID NO:29.

2. The method of claim 1 , wherein the capsid protein has at least 99% sequence identity to SEQ ID NO: 31.

3. The method of claim 1 , wherein the capsid protein has at least 99% sequence identity to SEQ ID NO: 29.

4. The method of claim 1 , wherein the capsid protein is identical to SEQ ID NO: 31.

5. The method of claim 1 , wherein the capsid protein has at least 97% sequence identity to SEQ ID NO: 29.

6. The method of claim 1 , wherein the capsid protein has the sequence of SEQ ID NO: 29.

7. The method of claim 1 , where said introducing comprises introducing via injection.

8. The method of claim 7 , wherein the mammal is a human.

9. The method of claim 1 , wherein the mammal is a human.

10. A method of transfer of a nucleic acid of interest into a cell, comprising: introducing a recombinant adeno-associated virus (AAV) vector into a cell, the recombinant AAV vector encoding a nucleic acid of interest encapsidated in a capsid protein that has at least 99% sequence identity to SEQ ID NO: 31 or at least 97% sequence identity to SEQ ID NO: 29.

11. The method of claim 10 , wherein the capsid protein has at least 99% sequence identity to SEQ ID NO: 31.

12. The method of claim 10 , wherein the capsid protein has the sequence of SEQ ID NO: 31.

13. The method of claim 10 , wherein the capsid protein has at least 97% identity to SEQ ID NO: 29.

14. The method of claim 10 , where said introducing comprises introducing in vitro.

15. The method of claim 10 , where said introducing comprises introducing in vivo.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2017
From: LISOWSKI, LESZEK; KAY, MARK A.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 044279/0288 →
Continuity (5)
Division 14853552 · Sep 14, 2015
Division 13594773 · Aug 24, 2012
Provisional Application 61545488 · Oct 10, 2011
Provisional Application 61526688 · Aug 24, 2011
Related Publication 20180258420A1 · Sep 13, 2018
Cited By (2)
US 12,467,065 US 12,534,717